Compare Raymond James Financial, Inc. (RJF) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs ResMed Inc. — how do they compare? Raymond James Financial, Inc. trades at $159.62 (market cap $30.51B), while ResMed Inc. trades at $229.83 (market cap $31.89B). The key difference: Raymond James Financial, Inc. and ResMed Inc. are close in size by market cap, and Raymond James Financial, Inc. pays the higher dividend (1.36%). Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 74 Days and ResMed Inc. for 51 Days on average.
| RJF | RMD | |
|---|---|---|
Market Cap | $30.51B | $31.89B |
Volume | 1,206,253 | 618,314 |
Sector | Financials | Health |
52-Week High | $181.18 | $277.88 |
52-Week Low | $140.89 | $182.82 |
Typical Hold Time | 74 Days | 51 Days |
Enterprise Value | $24.37B | $31.24B |
Dividend Yield | 1.36% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $157.29, down 1.4% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $3.14 surpassing the $2.93 forecast. Revenue growth is steady, reaching $13.84 billion in 2025, while profitability remains strong with a net income margin of 15.37%. Recent corporate news includes executive leadership appointments and a declared quarterly dividend of $0.54 per share.
The outlook is mixed, with a consensus analyst price target of $184.00 suggesting upside potential, but technical indicators signal near-term caution. Key risks include rising expenses and capital market volatility. The absence of sell ratings and solid institutional interest support a fundamentally sound investment case, though investors should weigh the bearish technical momentum against strong fundamentals.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
